A new technology, leadless pacemaker therapy, was recently introduced clinically to address lead-and pocket-related complications in conventional transvenous pacemaker therapy. These leadless devices are self-contained right ventricular single-chamber pacemakers implanted by using a femoral percutaneous approach. In this review of available clinical data on leadless pacemakers, early results with leadless devices are compared with historical results with conventional single-chamber pacing. Both presently manufactured leadless pacemakers show similar complications, which are mostly related to the implant procedure: cardiac perforation, device dislocation, and femoral vascular access site complications. In comparison with conventional transvenous single-chamber pacemakers, slightly higher short-term complication rates have been observed: 4.8% for leadless pacemakers versus 4.1% for conventional pacemakers. The complication rate of the leadless pacemakers is influenced by the implanter learning curve for this new procedure. No long-term outcome data are yet available for the leadless pacemakers. Larger leadless pacing trials, with long-term follow-up and direct randomized comparison with conventional pacing systems, will be required to define the proper clinical role of these leadless systems. Although current leadless pacemakers are limited to right ventricular pacing, future advanced, communicating, multicomponent systems are expected to expand the potential benefits of leadless therapy to a larger patient population.
A nnually, ≈1 million new pacemakers are implanted worldwide, of which 250 000 are implanted in the United States 1 for bradyarrhythmias and heart block. 2 Since the first pacemaker implants almost 6 decades ago, conventional transvenous pacemaker therapy has evolved tremendously, improving quality of life and reducing mortality in some at-risk patients. [2] [3] [4] [5] Despite these developments, this life-improving therapy is still associated with significant complications, mostly related to the transvenous lead and the subcutaneous generator pocket. Short-term complication rates as high as 8% to 12% have been reported, 6, 7 and include pneumothorax, cardiac tamponade, pocket hematoma, and lead dislodgement. [8] [9] [10] Transvenous leads can cause complications such as venous obstruction, tricuspid regurgitation, and endocarditis. 11, 12 Transvenous leadrelated endocarditis has been reported associated with a mortality risk as high as 12% to 31%. 13, 14 In the long term, these leads are also prone to insulation breaks and conductor fracture, requiring reintervention that puts the patient at risk for significant morbidity. 15, 16 Furthermore, 0.7% to 2.4% of patients encounter serious complications related to the subcutaneously placed pulse generator: skin erosion, pocket infection, and septicemia. [17] [18] [19] [20] To address these lead-and device pocket-related issues, leadless pacemaker systems were conceptualized in the 1970s 21, 22 and have been gradually developed. In 2012, a new single-chamber right ventricular leadless cardiac pacemaker was introduced. [23] [24] [25] [26] Development of these miniaturized devices was enabled by a number of advancements: (1) improvements in battery technology to allow adequate pacemaker longevity despite its low profile and overall size, (2) advances in component design including miniaturization and low power utilization, (3) communication protocols to also minimize power utilization, and (4) practical catheter-based delivery tools to negotiate the vasculature and cardiac anatomy and permit safe affixation to the myocardial wall. In this review, we describe the technology of the current clinically available leadless pacemaker devices and compare the early results with these devices with historical transvenous single-chamber pacemaker (VVI) cohorts.
SELF-CONTAINED LEADLESS PACEMAKERS FOR RIGHT VENTRICULAR PACING
Two leadless pacing systems are currently clinically available: (1) the Nanostim Leadless Cardiac Pacemaker (LCP; St. Jude Medical), and (2) the Micra Transcatheter Pacing System (TPS; Medtronic). Both are fully selfcontained units capable of providing single-chamber right ventricular pacing, sensing, and delivery of rate response. The Nanostim LCP received CE mark in October 2013, and is currently awaiting US Food and Drug Administration (FDA) approval. The Micra TPS received CE mark in April 2015 and FDA approval in April 2016. The 2 pacemakers are compared in Figure 1 . The Nanostim is longer (42 mm versus 25.9 mm); however, both displace similar volumes of 1.0 cc and 0.8 cc, respectively. The implant procedure for both systems is similar, utilizing a percutaneous femoral, catheter-based approach to introduce and advance the leadless pacemaker to the right ventricle (RV). The introducer sheaths are dedicated for the procedure and measure 18F (inner diameter)/21F (outer diameter) for the LCP, and 23F (inner diameter)/27F (outer diameter) for the TPS. After the pacemaker is advanced to the RV, contrast is injected to opacify the RV and visualize the desired location. The pacemaker is deployed by using either a screw-in helix (LCP) or nitinol tines (TPS) to actively fix the device to the myocardium. Both pacemakers use a sensor to provide rate response, albeit with varying approaches: a temperature-based sensor for the LCP and a 3-axis accelerometer for the TPS. After electric measurements are obtained, the stability of the fixated pacemaker is assessed by performing a gentle tug test. Subsequently, the pacemaker is released from the delivery catheter by removing/unlocking the tether. To establish communication for interrogation and programming, 2 different technologies are used: the LCP uses conductive communication with 5 ECG surface electrodes to minimize battery drain, whereas the TPS uses the conventional approach of radiofrequency current.
One important feature of leadless pacemaker systems is their retrievability. The LCP system has a dedicated steerable retrieval catheter for this purpose. When the distal cap of the pacemaker is captured by the snare of the retrieval catheter, it is designed to be removed by rotating, and, hence, unscrewing the pacemaker counterclockwise. The TPS system does not have a dedicated retrieval system, but has been shown in some cases to be retrievable by using a conventional gooseneck snare. After advancing the snare through the TPS delivery catheter, the cup of the delivery catheter is advanced while applying counter pressure and retracting the TPS to unfold the tines from the myocardium.
CLINICAL DATA ON SAFETY AND PERFORMANCE
The first human trial of leadless pacing therapy, the LEADLESS trial 23 (NCT 01700244) enrolled 33 patients at 3 centers between December 2012 and April 2013. Conducted to evaluate the clinical safety and performance of the Nanostim LCP, the patient and procedure characteristics are summarized in online-only Data Supplement Table I . The LCP was implanted successfully in 32 of 33 (97%) patients. The overall complication-free rate was 94% (31/33) at 90 days of follow-up (onlineonly Data Supplement Table II) . One major complication occurred: a 70-year-old man with a history of atrial fibrillation experienced cardiac tamponade with hemodynamic collapse during LCP implantation and required urgent cardiac surgery. Five days later, this patient with a nontherapeutic international normalized ratio level experienced an ischemic stroke and died 2 weeks later. The subsequent 12-month follow-up of these first 31 patients demonstrated adequate chronic electric performance and no device-related complications. 26 A second clinical study, the FDA investigational device exemption (IDE) trial, LEADLESS II (The LEADLESS Pacemaker IDE Study; NCT 02030418), was prospectively performed in 56 centers in 3 countries (USA, Canada, and Australia) to assess the safety and efficacy of the LCP system. 24 The study enrolled 526 patients (mean age 75±8 years, 62% male), 300 with a minimum followup of 6 months. The implantation success was 95.8% (504/526), mean procedure time was 28.6±17.8 minutes, and 70% of the patients did not require device repositioning. Device-related serious adverse events occurred in 34 (6.5%) patients. Pericardial effusion occurred in 1.5% for which all but 0.4% required intervention. Vascular complications occurred in 1.2% and device dislodgement in 1.1%. In the first 2 weeks after the device placement, 4 LCPs dislodged to the pulmonary artery, and 2 dislodged to the right femoral vein. All were percutaneously removed, and new LCPs were implanted. In addition, 0.8% of patients required device retrieval because of elevated pacing thresholds (range, 1-413 days). All complications are summarized in online-only Data Supplement Table II. The electric performance improved from baseline to 12 months: mean R-wave amplitude increased from7.8±2.9 mV to 9.2±2.9 mV (P<0.01), mean impedance decreased from 700±295Ω to 456±111Ω (P<0.01), and the mean pacing capture threshold at 0.4 ms decreased from 0.82±0.69 V to 0.58±0.31 V (P<0.01). The mean percentage pacing at 12-month follow-up was 51.6±39.1%. In a subgroup of 30 patients that underwent additional 24-hour Holter monitoring, the mean ventricular pacing rate was 50.3±39.9% (range, 0%-98%), the mean minimum and maximum heart rates were 58.6±9.2 beats/min and 111.1±21.1 beats/min, no pauses exceeded 2.0 seconds, and there were no episodes of undersensing or failure to capture. T-wave oversensing was noted in 4 (13%) of the 30 patients; none led to symptoms or adverse events.
Recently, a battery advisory with the Nanostim leadless pacemaker was issued by the manufacturer. In this initial communication, 7 of 1423 (0.5%) patients who had received an LCP device had a battery malfunction that occurred between 29 and 37 months postimplant. Additional follow-up will be necessary to fully appreciate the frequency of this issue. In these devices, PM failure resulted from abrupt battery depletion culminating in loss of pacing and communication. This battery issue Upper, The Nanostim LCP is displayed, including a detailed image of the fixation mechanism (screw-in helix), table with the system characteristics, and fluoroscopy images of the implant procedure. Lower, The Micra TPS is displayed, including a detailed image of the fixation mechanism (nitinol tines), table with the system characteristics, and fluoroscopy images of the implant procedure. LCP indicates Leadless Cardiac Pacemaker; RV, right ventricle; and TPS, Transcatheter Pacing System. seems to be limited to the Nanostim LCP; there is no evidence of any similar battery issue with the Micra TPS device. This episode highlights the fact that, as with any cardiac implantable pacemaker (or defibrillator), malfunctions can occur, and prospective long-term registry data are critical before reaching definitive conclusions about a device's performance.
The FDA IDE Micra TPS Trial (Micra Transcatheter Pacing Study; NCT02004873) was also a global, multicenter prospective study to evaluate device safety and efficacy. 25 In total, 725 patients (mean age 75.9±10.9 years, 58.8% male) who met a class I or II guideline indication for RV pacing were enrolled. In 99.2% of the patients, the implantation of the TPS was successful (n=719/725), with a mean procedure duration of 23.0±15.3 minutes. Major device-related complications occurred in 25 (3.4%) of the 725 patients, including cardiac perforations in 1.5%, vascular complications in 0.7%, venous thromboembolism in 0.3%, and increased pacing thresholds in 0.3% of patients. No device dislodgements were observed. One patient, a 77-year-old woman with end-stage renal failure, who underwent concomitant atrioventricular (AV) nodal ablation during the transcatheter pacemaker implantation, died. This was thought to be related to metabolic acidosis attributable to a prolonged procedure time with underlying renal failure.
The electric performance of the TPS during 6 months of follow-up showed stable measurements between implant and 6 months: mean R-wave amplitude of 11.2 mV and 15.3 mV, mean pacing capture threshold (at 0.24 ms) of 0.63 V and 0.54 V, and mean pacing impedance of 724Ω and 627Ω, respectively.
COMPARISON OF THE LEADLESS PACEMAKER SYSTEMS Complications
Overall, the 2 leadless systems have demonstrated comparable performance and safety results. As expected, pneumothorax and pocket/lead infection did not occur. However, the leadless procedure was associated with femoral vascular complications unique to the percutaneous insertion of the device, the need to reposition the device intraoperatively, and a moderate risk of cardiac perforation resulting in pericardial effusion. It is difficult to compare the complication rates of the 2 leadless pacemaker systems because of several differences in the 2 study designs. The main difference in these 2 trials was the definition used for the primary safety outcome. The LEADLESS II study used the standard ISO 14555 3.36 definition of Serious Device Adverse Effects: adverse events leading to (1) death, (2) serious deterioration in subject health resulting in either life-threatening illness, permanent impairment of body structure or function, inpatient or prolonged hospitalization, medical or surgical intervention to prevent life-threatening illness or permanent impairment, or (3) fetal distress, death, birth defects. In contrast, the Micra TPS study used a self-defined end point named Major Complications; this was defined as adverse events that resulted in death, permanent loss of device function, hospitalization or prolonged hospitalization (>48 hours), or a system revision (explant, reposition, replacement). Thus, adverse events requiring medical or surgical intervention but not leading to the criteria mentioned above would not have been included. Indeed, if this Major Complication criterion were applied to the LEADLESS II study, the complication rate would have decreased from the reported 6.5% to 4.9%.
Although the pericardial effusion rates for the devices were similar (1.5% in each), there was a difference in the device dislodgement rate between the LCP and TPS (2.3% versus 0%). This indicates that the screw-in fixation mechanism of the LCP may be at a higher risk for dislocation. The design of the LCP requires a balance between adequate fixation and excessive myocardial penetration. Excessive penetration may lead to cardiac perforation, whereas insufficient penetration risks device embolization. Achieving fixation of the LCP is experience related. Indeed, evidence for this was seen in the ongoing European LEADLESS Observational Trial (NCT02051972). In the early phase of this study in 2014, there were 2 instances of fatal pericardial tamponade that resulted in a temporary pause of the European study and subsequent enhanced physician training. The device dislodgement rates substantially reduced from 2 (1.4%) of 147 implants prepause to 0 of 93 postpause. 27 Enhanced physician training with a focus on performing a deflection test to test adequate fixation before device release, and electric mapping of the myocardial tissue before fixation, was likely, at least in part, responsible for this substantial reduction in device dislodgements. This underscores the importance of proper physician training and highlights the inevitable occurrence of a learning curve with new technology. The occurrence of a learning curve was also demonstrated in the LEADLESS II trial, in which Serious Device Adverse Effects were less frequently observed after 10 implants per operator (6.8%-3.6%). In the Micra study, there was no evidence of a relationship between operator experience and major complications. 28 On the other hand, the investigators 25 were able to identify several characteristics of patients likely to experience cardiac injury (n=13/725, 1.7%): older age, female sex, low body mass index, and chronic lung disease. If substantiated in larger studies, this information might help physicians in optimizing patient selection.
Longevity
Using the 6-month follow-up actual-use data, the estimated battery longevity was 15.0 years for the LCP and 12.5 years for the TPS. There are several important caveats to consider when interpreting these results. First, the projections are made using relative short-term data (6 months), limiting the robustness of extrapolation to long-term battery longevity. Indeed, previous studies with standard pacemakers have shown a discrepancy between estimations and actual battery longevity. 13, 29 Furthermore, different methods to estimate battery longevity have been used for the 2 devices, with significant influence on projected longevity. The LCP used the (ISO standard) nominal settings of 100% pacing at 2.5 V at 0.4 ms at 60 beats/min. The TPS used an alternative nominal setting of 100% pacing at 1.5 V at 0.24 ms at 60 beats/min. If the TPS longevity estimate was instead calculated by using the ISO nominal settings, the battery longevity drops to 4.7 years. 30 On the other hand, the TPS has an autocapture algorithm feature, which is not available in the LCP, optimizing the pacing output to 0.5 V above the pacing threshold. Although this should prolong battery longevity significantly, it implies a smaller capture safety margin: an issue to consider in pacemaker-dependent patients. Ultimately, long-term battery longevity of these leadless devices will need to be scrutinized.
Retrievability versus Abandonment
Both leadless pacemaker systems are designed to be retrieved if necessary, and recent publications support acute and midterm retrievability. [31] [32] [33] [34] [35] [36] [37] The LCP has a dedicated retrieval catheter available with either a single-loop or triloop snare, and has a screw-in fixation mechanism that may facilitate atraumatic removal (Figure 2) . The largest retrieval experience with the LCP includes 16 patients (77±13 years, 75% male) who required device removal for either elevated pacing thresholds (8 patients), worsening heart failure (5 patients), failure to pace (1 patient), upgrade to defibrillator (1 patient), or elective explantation (1 patient). Catheter-based retrieval was successful in 15 of 16 patients (94%) without the occurrence of retrieval-related Serious Device Adverse Effects (no pericardial effusions occurred). The mean time from implant to retrieval was 240 days (range, 1-1188 days). 31 Although this experience includes only a small number of patients followed for a mean implant-to-retrieval time of less than a year, there is some preclinical evidence that retrieval of this device may be possible more long term. In an ovine study, LCP retrieval was 100% successful in 8 sheep in which devices had been implanted for a mean of 2.3±0.1 years. 32 Pathological examination of these animals showed no visible tissue on the body on the LCPs, little fibrous tissue around the proximal docking button, and no evidence of pericardial perforation Figure 2 . Retrieval of the leadless pacemaker systems.
Upper, The Nanostim LCP is retrieved using a dedicated single-loop retrieval catheter (18F). First, the LCP is captured by maneuvering the single snare of the retrieval catheter around the docking button of the LCP. Then, the LCP is docked to the retrieval catheter and rotated counterclockwise to disengage the screw-in helix from the myocardial tissue. Subsequently the protective sleeve is advanced over the LCP and the LCP is removed. Lower, The Micra TPS is removed using a grandmothermother-child technique used to direct the snare at the proximal retrieval feature. The snare is tightened around the waist of the retrieval feature and the TPS is removed from the myocardial tissue by pulling back the device while exerting moderate counter pressure using the sheaths. LCP indicates Leadless Cardiac Pacemaker; and TPS, Transcatheter Pacing System. TPS figures reprinted from Koay et al 34 with permission of the publisher. Copyright © 2016, Elsevier, Inc.
or adhesions at necropsy. Local endocardial response to the implanted LCP at the RV apex appeared limited; however, some localized (sub)endocardial hemorrhage at the implant site was observed. The rate of fibrous tissue formation and extent of device encapsulation observed in this ovine model may or may not relate to human implants. Although minimal fibrous tissue was observed on the retrieved LCPs in the human cases, fibrous device encapsulation after only 19 months has been reported. 38 There may be patient-specific factors that influence the progression and rate of fibrous capsule formation, but additional information is required for full characterization.
For the TPS system, 13 patients required a system revision because of elevated thresholds, pacemaker syndrome, need for biventricular pacing, or, in 1 patient, device infection. Retrieval using a gooseneck snare was successful without complications in 8 of 10 patients in whom it was attempted. In the remaining 2, plus 3 others in whom retrieval was not attempted, the device was turned off and left in situ. 37 Full encapsulation of the TPS has been observed and might complicate the recapture of the distal end of the device. 39, 40 Given the smaller length of the TPS (relative to the LCP), this is not surprising.
Considering the uncertainty of long-term retrieval attributable to device encapsulation, the optimal end-of-life replacement strategy is yet to be defined. One strategy, which already has been exercised with the TPS, is to abandon a turned-off leadless pacemaker in the RV. The small volume of these leadless devices (0.8-1.0 cc) accounts for <2% the volume of a normal-sized RV 41 and is quite unlikely to cause hemodynamic compromise.
Preclinical studies showed the feasibility of multiple (up to 3) TPS implants in a porcine and human cadaveric model. 42, 43 On echocardiographic assessment in 14 minipigs, there were no significant changes in left ventricular ejection fraction or changes in tricuspid regurgitation. The mean length of device encapsulation after 215±7 days was 14.3±7.8 mm, which translates to little over half the length of the TPS. 42 The vast clinical experience with transvenous pacemaker or defibrillator lead abandonment without reported detrimental effects on RV function support this strategy. Unknowns for this strategy are the maximum number of devices that can be placed in parallel mechanical or electric interactions in the human anatomy.
HISTORICAL VVI PACEMAKER COHORTS
A literature search was performed to identify all studies with single-chamber ventricular (VVI) pacemaker cohorts with (1) at least 100 patients enrolled, and (2) all complications were reported specifically for single-chamber ventricular pacemakers. The study details, patient demographics, and available procedure information are shown in online-only Data Supplement Table I . Both randomized controlled trial data and prospective/retrospective observational data were included, unavoidably introducing selection bias into the results. A total of 14 330 patients with a single-chamber pacemaker (mean age 79.1 years, 55.8% male) from 10 studies 4,5,12,44-50 were evaluated. The complications were classified in 2 categories: short-term (≤2 months) and long-term complications (>2 months). In the overall cohort, short-term device-related complications were reported in a total of 4.0% patients and were mostly related to the implant procedure: these included pneumothorax (0.6%), acute lead dislocation (0.4%), cardiac perforation (0.1%), and hematoma (0.3%) (online-only Data Supplement Table II ). Four of the 10 studies reported long-term complication rates in a total of 3176 patients with a mean follow-up of 66 months. Of these, 98 (3.1%) experienced a long-term complication, mostly related to the pacemaker pocket (eg, infection/erosion 0.9%) or to the transvenous leads (0.6%). It should be noted that there were substantial differences in the complication rates in these individual studies: short-term complication rates ranged from 1.5% to 11.8%, and long-term complication rates ranged from 1.3% to 6.9%.
COMPARISON OF LEADLESS VERSUS TRADITIONAL VVI PACING
The patient and procedure characteristics are shown in Table 1 . The short-term complication rate of the conventional pacemaker (4.0%) appears slightly superior to that observed for the leadless pacemakers (4.8%) ( Table 2) . Two important factors influence this difference. First, conventional pacemaker technology has matured over 50 years of development, and its implantation technique is well established. Conversely, leadless pacing is a novel technology for which the procedure learning curve was included in the clinical trials. Indeed, the mean number of procedures performed per operator in the LEADLESS II and Micra studies were only 5.3 and 7.7, respectively. Second, there may be some underreporting of complications in the transvenous pacemaker studies, because these studies did not mandate careful follow-up with site-level independent monitoring, unlike the prospective leadless FDA IDE trials.
When assessing the types of complications, an increased risk of cardiac perforation and pericardial effusion is apparent with the leadless pacemakers (1.5% versus 0.1%). This may be partly related to the size of the fixation mechanism being more extensive with the leadless pacemakers, but the importance of a learning curve cannot be ignored. Furthermore, newer generations of device and delivery tools will invariably be designed to further decrease these risks. Last, there is recent realworld data from a large US cohort (n=922 549) that has highlighted an increasing rate of cardiac tamponade in patients after conventional pacemaker placement: from 0.26% in 2008 to 0.35% in 2012, translating to an increase in in-hospital mortality. 51 This 35% increase in tamponade is thought to be related to an increase in the comorbidity profile of the population of patients receiving pacemakers. Femoral vascular access site complications were unique to the leadless pacemakers (0.9% versus 0%), but typically require only conservative management (eg, extended pressure bandage). Acute device/lead dislodgement rates were similar between groups (0.5% versus 0.6%), but may be more threatening if the leadless device embolizes to the pulmonary artery. As expected, pneumothorax development did not occur with leadless pacemaker implantation (1 instance of hemothorax was noted), but remains a challenge for transvenous pacemaker implantation despite an increased use of cephalic venous access (0% versus 0.6%). A difference in mean fluoroscopy times was observed between the leadless and transvenous pacemakers (11.0 minutes versus 3.7 minutes), but this may decrease as experience accrues.
No long-term outcome data are yet available for leadless pacemakers. Thus no comparison can be drawn between long-term outcomes of the leadless and conventional pacemaker systems. This is important, be- AF indicates atrial fibrillation; AVB, atrioventricular block; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; Fluoro, fluoroscopy; FUP, follow-up; HT, hypertension; LVEF, left ventricular ejection fraction; MI, myocardial infarction; N/A, no data were available; NSR, normal sinus rhythm; PCI, percutaneous coronary intervention; Pros, prospective observational analysis; RCT, randomized controlled trial; Retro, retrospective observational analysis; RV, right ventricle; SND, sinus node dysfunction; and TIA, transient ischemic attack.
*Estimated battery longevity at 6-month FUP. cause any potential advantage of leadless pacemakers is anticipated over the long term, when complications related to the device pocket and leads of standard pacemakers occur. This was hinted at in 2 observations. First, the 1-year outcomes from the LEADLESS II LCP cohort were recently compared with a matched cohort of patients undergoing standard single-chamber pacemaker implantation; these data were obtained from the Truven MarketScan database, which tracks US healthcare claims and Medicare supplemental insurance encounters. 52 In brief, from a total cohort of 120 556 patients undergoing pacemaker implantation between 2009 to 2014, 10 492 adult patients receiving single-chamber pacemakers were identified and matched for age, sex, and various comorbidities to provide a propensity-matched cohort of 2154 patients. This real-world experience revealed a 71% reduction in complications observed with LCP procedures relative to standard pacemakers, with substantial reductions seen in both short-term (defined as ≤1 month postimplant) and midterm (defined as 1-24 months postimplant) complications.
Second, a recent report compared the 1-year outcomes from the Micra TPS cohort with a predefined historical control group of standard pacemaker patients (n=2662 patients). 53 In addition to a 48% lower 1-year complications rate with the TPS patients relative to standard pacemakers, there were also 47% fewer hospitalization over the time period, driven in part by an 82% reduction in the need for pacemaker system revision.
Of course, both of these reports are limited by their retrospective nature and the confounding possibility of bias attendant with such comparisons. It is clear that longer follow-up of patients who have leadless pacemaker is required to definitively appreciate long-term complication rates. Ultimately, randomized controlled studies comparing leadless and conventional pacemakers are necessary to fully assess their durability and relative role in clinical practice.
CLINICAL APPLICABILITY
At this point, both leadless pacemaker systems are right ventricular single-chamber pacemakers only. Such devices serve a minority (15%-30%) of total pacemaker recipients in Western countries 1 : mainly patients with chronic atrial fibrillation and AV block. However, current guidelines for single-chamber pacing 2 also recommend consideration in patients with complete AV block who are elderly and have a low activity level, and patients with sinus node dysfunction and infrequent pauses. Indeed, if leadless pacing proves to be durable and at least as effective as transvenous pacing, its availability may broaden the use of single-chamber pacing to include patients who otherwise might receive a dual-chamber device. In the leadless studies, 60% of patients had chronic atrial fibrillation with AV block, 25% had high-degree AV block and 15% had sinus node dysfunction. On the other hand, RV pacing can be detrimental in some patients, especially those with marginal ejection fractions in whom heart failure might develop. 54 †Three patients (3/1284) were admitted for worsening heart failure.
TRAINING FOR LEADLESS PACEMAKER IMPLANTATION
One important consideration is the manner of elaboration of this novel technology beyond the clinical trials to clinical practice. With regard to the physicians that should be performing leadless pacemaker implantation, it probably matters less the type (electrophysiologist, nonelectrophysiologist pacemaker-implanting cardiologist, or cardiac surgeon), but it is important for the physician to have the necessary skills: (1) technical, particularly catheter experience including vascular access/management, and catheter manipulation within the heart, and (2) cognitive, such as pacemaker indications, programming, and troubleshooting. Given that the skills for acute device retrieval overlap with those for device implantation, it is less necessary to have experience with lead extraction, a somewhat specialized skill. Of course, Figure 3 . Overview of leadless cardiac device concepts.
In this figure, an overview of leadless device concepts is displayed. For bradycardia pacing, leadless device concepts include leadless single-chamber and dual-chamber pacemakers, consisting of communicating leadless modules. Single-chamber leadless pacing is currently available. The subcutaneous implantable cardioverter defibrillator (S-ICD) currently provides defibrillation therapy without using a transvenous lead. Future concepts include adding a leadless pacing component to the S-ICD capable of providing both brady-and antitachypacing therapy. Furthermore, leadless cardiac resynchronization therapy concepts include self-contained or externally powered leadless pacers in the right atrium, right ventricle, and left ventricle (LV). Once combined with an S-ICD, this system could provide leadless cardiac resynchronization therapy. In the middle, a future universal leadless device concept is portrayed consisting of communicating leadless pacing components placed in the right atrium, right ventricle and left ventricle, an S-ICD, coupled with a pulmonary pressure monitor providing CRT-D therapy and heart failure monitoring in 1 leadless device system that has the potential to further optimize cardiac device management therapy. CRT-D indicates cardiac resynchronization therapy device; and CRT-P, cardiac resynchronization therapy pacemaker. it is unknown if additional skills will be required for longterm device retrieval. Once the operator is identified, the manufacturers have designed simulation systems for training the operator, including manipulating the catheter delivery tools on the benchtop; actual preclinical experience, while useful if possible, is probably not necessary. However, proctoring for device implantation should be mandatory for the initial procedures, at least for the first 10. The nature of the proctor is less critical, whether a physician or a properly trained industry clinical specialist. Last, given the differences between the implants from the various manufacturers, proctoring should be considered independently for each device; that is, proctored implants with 1 device should not count for the other device.
FUTURE PERSPECTIVES
To expand the benefits of leadless pacing to more patients, efforts are being made to develop multicomponent, communicating leadless systems capable of performing dual-chamber pacing and cardiac resynchronization therapy (Figure 3) . 55, 56 Although not strictly a self-contained leadless pacemaker system, another leadless pacing system that is being investigated clinically 57, 58 bears mentioning. This novel system consists of 2 components: (1) a leadless pacing electrode (≈0.05 cc displacement) that is affixed to the endocardial left ventricular free wall, and (2) a subcutaneous ultrasonic transmitter and battery that synchronizes to a conventional right-sided pacing system and emits ultrasonic pulses. The pacing electrode converts this ultrasound energy into electric stimuli resulting in left ventricular stimulation for cardiac resynchronization. A large multicenter FDA IDE clinical trial of this system is planned to commence in the near future.
Beyond pacing, it is also anticipated that leadless pacing may be combined with defibrillation therapy (Figure 3) . Although there is no clinical experience with any such dedicated combination, there are reports of concomitant, but not communicative independent implantation of subcutaneous defibrillators and leadless pacemakers. 59, 60 Furthermore, a third leadless pacemaker system that can deliver antitachycardia pacing when coupled with a subcutaneous defibrillator was successfully tested preclinically. 61 Clinical trials of this combination therapy are expected to commence in the near future.
Beyond pacing and defibrillation, leadless device-todevice communication may enable the intriguing possibility of further integration with patient-monitoring devices (Figure 3 ). For example, in the future, a patient with congestive heart failure might receive a communicative device system consisting of: (1) right atrial, right ventricular, and left ventricular leadless pacers for cardiac resynchronization, (2) a subcutaneous defibrillator for sudden death prophylaxis, and (3) a pulmonary artery pressure monitor for heart failure monitoring.
CONCLUSION
The first 2 leadless pacemaker systems have demonstrated similar performance and initial promise of efficacy and safety. A significant implanter learning curve has been appreciated. No long-term performance data of the leadless systems are yet available to determine technological robustness. As leadless pacing matures, both in device technology and physician experience, procedure-related complications are likely to decrease. Randomized controlled trials comparing leadless and conventional devices are necessary to fully appreciate any differences between these technologies in clinical practice. 
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